[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-381087-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-381087-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","could-dna-fragments-be-the-key-to-early-detection-of-lung-cancer","Could DNA Fragments Be the Key to Early Detection of Lung Cancer?","","Lung cancer remains a leading cause of cancer-related mortality, and while annual low-dose computed tomography screening can reduce mortality, broad population implementation is limited by eligibility challenges and concerns about false positives, radiation exposure, and invasive diagnostic morbidity. The article examines how noninvasive blood-based approaches may address these limitations by interrogating circulating cell-free DNA, including tumor-derived ctDNA, using sensitive sequencing to detect early genetic and epigenomic changes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/could-dna-fragments-be-the-key-to-early-detection-of-lung-cancer/381087/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/could-dna-fragments-be-the-key-to-early-detection-of-lung-cancer/381087.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is population-level LDCT screening difficult to implement?","Question",{"text":63,"@type":64},"Implementation is limited by challenges in eligibility determination and by concerns over false-positive imaging results, radiation exposure, and the morbidity from invasive follow-up diagnostic procedures.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is cell-free DNA (cfDNA) and where does it come from?",{"text":68,"@type":64},"Plasma cfDNA arises from chromatin fragmentation during cell death, is shed into circulation, and can be isolated from plasma collected via routine blood draw.",{"name":70,"@type":61,"acceptedAnswer":71},"How does ctDNA support early lung cancer detection?",{"text":72,"@type":64},"ctDNA is tumor DNA specifically shed from cancer cells and can be detected using highly sensitive sequencing assays to identify tumor-specific genetic alterations, enabling a noninvasive “liquid biopsy” approach for early-stage disease.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},381087,1790863192,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":111},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","EDITORIALS  \nmortality: a genome-wide association study. Lancet Respir Med 2013;  \n1:309–317.  \n18. Zhang D, Newton CA, Wang B, Povysil G, Noth I, Martinez FJ, et al.  \nUtility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosis. Eur Respir J 2022;60:  \n2200577.  \n19. Peljto AL, Blumhagen RZ, Walts AD, Cardwell J, Powers J, Corte TJ, et al. ; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Idiopathic pulmonary fibrosis is associated with common genetic variants and limited rare variants. Am J Respir Crit Care Med 2023;207:1194–1202.  \n20. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022;205:e18–e47 .  \n21. Zhou W, Kanai M, Wu K-HH, Rasheed H, Tsuo K, Hirbo JB, et al. ; Biobank of the Americas; Biobank Japan Project; BioMe; BioVU; CanPath-Ontario Health Study; China Kadoorie Biobank Collaborative Group; Colorado Center for Personalized Medicine; deCODE Genetics; Estonian Biobank; FinnGen; Generation Scotland; Genes & Health Research Team; LifeLines; Mass General Brigham Biobank; Michigan Genomics Initiative; National Biobank of Korea; Penn Medicine BioBank; Qatar Biobank; QSkin Sun and Health Study; Taiwan Biobank; HUNT Study; UCLA ATLAS Community Health Initiative;  \nUganda Genome Resource; UK Biobank. Global Biobank Metaanalysis Initiative: powering genetic discovery across human disease. Cell Genom 2022;2:100192 .  \n22. Koskela JT, H€app€ol€a P, Liu A, Partanen J, Genovese G, Artomov M, et al. Genetic variant in SPDL1 reveals novel mechanism linking pulmonary fibrosis risk and cancer protection [preprint] . medRxiv; 2021 [accessed 20 Jan 2023]. Available from: [https://www.medrxiv.org/](https://www.medrxiv.org/)[ ](https://www.medrxiv.org/)[content/10.1101/2021.05.07.21255988v1.](content/10.1101/2021.05.07.21255988v1.)  \n23. Donoghue LJ, Stockwell AD, Neighbors M, Sheng RX, Prabhakaran R, Wolters PJ, et al. Identification of a genetic susceptibility locus for idiopathic pulmonary fibrosis in the 16p subtelomere using whole genome sequencing. Am J Respir Crit Care Med 2023;206: 941–944.  \n24. Zhang D, Povysil G, Newton CA, Maher TM, Molyneaux PL, Noth I, et al. Genome-wide enrichment of TERT rare variants in idiopathic pulmonary fibrosis patients of Latino ancestry Am J Respir Crit Care Med 2022; 206:903–905.  \n25. Wheelock CE, Rappaport SM. The role of gene-environment interactions in lung disease: the urgent need for the exposome. Eur Respir J 2020; 55:1902064 .  \nCopyright © 2023 by the American Thoracic Society  \nCould DNA Fragments Be the Key to Early Detection of Lung Cancer?  \nIn the United States, lung cancer remains the leading cause of cancerrelated mortality, accounting for an estimated 136,000 deaths in 2023 (1). The survival of patients with lung cancer at 5 years after diagnosis has improved to23%, although it remains considerably lower than survival rates observed for other common cancers such as breast, colon, and prostate cancer. Multiple clinical trials have now confirmed the efficacy of annual low-dose computed tomographic (LDCT) screening in reducing lung cancer mortality (2–4); however, the implementation of LDCT screening at the population level has provendifficult because of challenges in eligibility determination and concerns regarding potential harm from false-positive imaging results, radiation exposure, and morbidity from invasive diagnostic procedures (5). Internationally, lung cancer screening implementation remains limited; although there has been more rapid uptake in some countries in Asia, the inclusion of low-risk individuals may influence population-level outcomes (6, 7). Thus, in the short run, the use of LDCT is likely to have only a limited impact on the global disease burden of lung cancer. Advocates of alternative noninvasive  \nThi","cbCairelWK6b3xm2","https://ap.wps.com/l/cbCairelWK6b3xm2","pdf",604120,"English","# Could DNA Fragments Be the Key to Early Detection of Lung Cancer?\n## Current limits of LDCT screening\n## Role of circulating cfDNA and ctDNA","[{\"question\":\"Why is population-level LDCT screening difficult to implement?\",\"answer\":\"Implementation is limited by challenges in eligibility determination and by concerns over false-positive imaging results, radiation exposure, and the morbidity from invasive follow-up diagnostic procedures.\"},{\"question\":\"What is cell-free DNA (cfDNA) and where does it come from?\",\"answer\":\"Plasma cfDNA arises from chromatin fragmentation during cell death, is shed into circulation, and can be isolated from plasma collected via routine blood draw.\"},{\"question\":\"How does ctDNA support early lung cancer detection?\",\"answer\":\"ctDNA is tumor DNA specifically shed from cancer cells and can be detected using highly sensitive sequencing assays to identify tumor-specific genetic alterations, enabling a noninvasive “liquid biopsy” approach for early-stage disease.\"}]","Could DNA Fragments Be the Key to Early Detection of Lung Cancer? | PDF",1790243516]